AXL and neoplasm: During preclinical research with DS-1205b (the sulfate trihydrate of DS-1205a [the free form of DS-1205c]), high expression of AXL was observed in tumors that were resistant to long-term administration of osimertinib, while the combination of DS-1205b and osimertinib strongly suppressed tumor growth [16].